Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1148/radiol.2332031800
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sironi, S.
Right arrow Articles by Fazio, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sironi, S.
Right arrow Articles by Fazio, F.
(Radiology 2004;233:433-440.)
© RSNA, 2004


Nuclear Medicine

Integrated FDG PET/CT in Patients with Persistent Ovarian Cancer: Correlation with Histologic Findings1

Sandro Sironi, MD, Cristina Messa, MD, Giorgia Mangili, MD, Barbara Zangheri, MD, Giovanni Aletti, MD, Elisabetta Garavaglia, MD, Riccardo Vigano, MD, Maria Picchio, MD, Gianluca Taccagni, MD, Alessandro Del Maschio, MD and Ferruccio Fazio, MD

1 From the School of Medicine, University of Milano-Bicocca, Milan, Italy (S.S., C.M., B.Z., F.F.); Institute for Molecular Imaging and Physiology of the National Research Council of Italy, Milan (S.S., C.M., F.F.); and Departments of Nuclear Medicine (C.M., M.P., F.F.), Gynecology and Obstetrics (G.M., G.A., E.G., R.V.), Pathology (G.T.), and Radiology, University Vita-Salute (A.D.M.), Institute H S.Raffaele, Via Olgettina 60, 20132 Milan, Italy. Received November 7, 2003; revision requested January 15, 2004; revision received February 4; accepted March 2. Address correspondence to F.F. (e-mail: fazio.ferruccio@hsr.it).

PURPOSE: To prospectively evaluate the accuracy of integrated positron emission tomography (PET) and computed tomography (CT) for depiction of persistent ovarian carcinoma after first-line treatment, with use of histologic findings as the reference standard.

MATERIALS AND METHODS: Thirty-one women (mean age, 55.9 years) with ovarian carcinoma treated with primary cytoreductive surgery and followed up with platinum regimen chemotherapy were included. All 31 patients were scheduled for surgical second-look. Before surgical second-look, all patients underwent fluorodeoxyglucose (FDG) PET/CT. At PET/CT, three main categories of persistent disease were considered for data analysis: lymph nodal lesion, peritoneal lesion, and pelvic lesion. In all patients, imaging findings were compared with results of histologic examination after surgical second-look to determine the diagnostic accuracy of PET/CT in the evaluation of disease status. The {kappa} statistic (Cohen {kappa}) was used for statistical analysis.

RESULTS: Seventeen (55%) of 31 patients had persistent tumor at histologic analysis after surgical second-look, and fourteen (45%) had no histologically proved tumor. The total number of lesions that was positive for tumor cells at histologic analysis was 41 (lymph nodes, n = 16; peritoneal lesions, n = 21; pelvic lesions, n = 4); maximum diameter of these lesions was 0.3–3.2 cm (mean, 1.7 cm). A correlation was found between PET/CT and histologic analysis ({kappa} = 0.48). The overall lesion-based sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of PET/CT were 78%, 75%, 77%, 89% and 57%, respectively. In the detection of a tumor, a size threshold could be set at 0.5 cm, as this was the largest diameter of a lesion missed at PET/CT.

CONCLUSION: Integrated PET/CT depicts persistent ovarian carcinoma with a high positive predictive value.

© RSNA, 2004

Index terms: Computed tomography (CT), comparative studies, 852.12111 • Dual-modality imaging, PET/CT, comparative studies • Positron emission tomography (PET), comparative studies, 852.12163 • Ovary, CT, 852.12111 • Ovary, neoplasms, 852.39 • Ovary, PET, 852.12163 • Ovary, radionuclide studies, 852.12163




This article has been cited by other articles:


Home page
JNMHome page
J. Czernin, M. Allen-Auerbach, and H. R. Schelbert
Improvements in Cancer Staging with PET/CT: Literature-Based Evidence as of September 2006
J. Nucl. Med., January 1, 2007; 48(1_suppl): 78S - 88S.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
G. K. von Schulthess, H. C. Steinert, and T. F. Hany
Integrated PET/CT: Current Applications and Future Directions
Radiology, February 1, 2006; 238(2): 405 - 422.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
N. Pandit-Taskar
Oncologic Imaging in Gynecologic Malignancies
J. Nucl. Med., November 1, 2005; 46(11): 1842 - 1850.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
T. M. Blodgett, B. Casagranda, D. W. Townsend, and C. C. Meltzer
Issues, Controversies, and Clinical Utility of Combined PET/CT Imaging: What Is the Interpreting Physician Facing?
Am. J. Roentgenol., May 1, 2005; 184(5_supp): S138 - S145.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2004 by the Radiological Society of North America.